Solid-state mAbs and ADCs subjected to heat-stress stability conditions can be covalently modified with buffer and excipient molecules

Journal of Pharmaceutical Sciences

Volumn 104, Issue 2, 2015, Pages 652-665

  Valliere Douglass, John F ^a   Lewis, Patsy ^a   Salas Solano, Oscar ^a   Jiang, Shan ^a  

^a NONE

Author keywords

Capillary electrophoresis; Charge variants; Covalent modification; Esterification; Excipients; Freeze drying lyophilization; Mass spectrometry; Stability

Indexed keywords

ANTIBODY DRUG CONJUGATE; BUFFER; EXCIPIENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY STRUCTURE; ARTICLE; CAPILLARY ISOELECTRIC FOCUSING; CHEMICAL MODIFICATION; CONTROLLED STUDY; COVALENT BOND; FEMALE; FREEZE DRYING; GEL PERMEATION CHROMATOGRAPHY; HEAT STRESS; HEAT TOLERANCE; MASS SPECTROMETRY; NONHUMAN; PEPTIDE MAPPING; PROTEIN MODIFICATION; SOLID STATE; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; HAMSTER; HEAT SHOCK RESPONSE; PHYSIOLOGY; PROTEIN STABILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BUFFERS; CHO CELLS; CRICETINAE; CRICETULUS; EXCIPIENTS; HEAT-SHOCK RESPONSE; PROTEIN STABILITY;

EID: 84922848257     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24276     Document Type: Article

References (59)

1. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6:903-918.
2. Carpenter JF, Chang BS. 1996. Lyophilization of protein pharmaceuticals. In Biotechnology and biopharmaceutical manufacturing, processing and preservation; Avisand K, Wu V, Eds. Buffalo Grove, Illinois: Interpharm Press, pp 199-263.
3. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27:544-575.
4. Sluzky V, Tamada JA, Klibanov AM, Langer R. 1991. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci USA 88:9377-9381.
5. Costantino HR, Langer R, Klibanov AM. 1994. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J Pharm Sci 83:1662-1669.
6. Costantino HR, Langer R, Klibanov AM. 1994. Moisture-induced aggregation of lyophilized insulin. Pharm Res 11:21-29.
7. Costantino HR, Langer R, Klibanov AM. 1995. Aggregation of a lyophilized pharmaceutical protein, recombinant human albumin: Effect of moisture and stabilization by excipients. Biotechnology (NY) 13:493-496.
8. Zhang W, Czupryn JM, Boyle PT, Jr., Amari J. 2002. Characterization of asparagine deamidation and aspartate isomerization in recombinant human interleukin-11. Pharm Res 19:1223-1231.
9. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98:2909-2934.
10. Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, Pan O, Sun J, Hokom M, Goletz TJ, Wypychet J, Zhou L, Kerwin BA, Narhi LO, Arora T. 2013. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. J Pharm Sci 102:3545-3555.
11. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, et al. 2014. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287:25266-25279.
12. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH)in development of antibodies to hGH. J Clin Endocrinol Metab 51:691-7.
13. Cacia J, Keck R, Presta LG, Frenz J. 1996. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity. Biochemistry 35:1897-1903.
14. Chelius D, Rehder DS, Bondarenko PV. 2005. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem 77:6004-6011.
15. Liu H, Gaza-Bulseco G, Sun J. 2006. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci 837:35-43.
16. Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, Liu JL. 2007. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry 46:1534-1544.
17. Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, Vardanyan L, Perico N, Mukku V, Brems DN, et al. 2008. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry 47:2518-2530.
18. Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, Kirchmeier M, Corvaia N, Ionescu R, Beck A. 2009. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 392:145-154.
19. Li B, O'Meara MH, Lubach JW, Schowen RL, Topp EM, Munson EJ, Borchardt RT. 2005. Effects of sucrose and mannitol on asparagine deamidation rates of model peptides in solution and in the solid state. J Pharm Sci 94:1723-1735.
20. Wakankar AA, Borchardt RT. 2006. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 95:2321-2336.
21. Wakankar AA, Liu J, Vandervelde D, Wang YJ, Shire SJ, Borchardt RT. 2007. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. J Pharm Sci 96:1708-1718.
22. Pace AL, Wong RL, Zhang YT, Kao YH, Wang YJ. 2013. Asparagine deamidation dependence onbuffer type, pH, and temperature. J Pharm Sci 102:1712-1723.
23. Santana H, Gonzalez Y, Campana PT, Noda J, Amarantes O, Itri R, Beldarrain A, Paez R. 2013. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: Effect of pH, buffers, and excipients. Int J Pharm 452:52-62.
24. Sinha S, Zhang L, Duan S, Williams TD, Vlasak J, Ionescu R, Topp EM. 2009. Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. Protein Sci 18:1573-1584.
25. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J. 2011. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. JBiol Chem 286:25134-25144.
26. Ouellette D, Chumsae C, Clabbers A, Radziejewski C, Correia I. 2013. Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule. mAbs 5:432-444.
27. Boyd D, Kaschak T, Yan B. 2011. HIC resolution of an IgG1 with an oxidized Trp in a complementarity determining region. J Chromatogr B Analyt Technol Biomed Life Sci 879:955-960.
28. Chumsae C, Gaza-Bulseco G, Sun J, Liu H. 2007. Comparisonofmethionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 850:285-294.
29. Stroop SD, Conca DM, Lundgard RP, Renz ME, Peabody LM, Leigh SD. 2011. Photosensitizers form in histidine buffer and mediate the photodegradation of a monoclonal antibody. J Pharm Sci 100:5142-5155.
30. Lam XM, Yang JY, Cleland JL. 1997. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86:1250-1255.
31. Ji JA, Zhang B, Cheng W, Wang YJ. 2009. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: Mechanisms and stabilization. J Pharm Sci 98:4485-4500.
32. Li S, Patapoff TW, Overcashier D, Hsu C, Nguyen TH, Borchardt RT. 1996. Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state. J Pharm Sci 85:873-877.
33. Fischer S, Hoernschemeyer J, Mahler HC. 2008. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm 70:42-50.
34. Brady LJ, Martinez T, Balland A. 2007. Characterization of nonenzymatic glycation on a monoclonal antibody. Anal Chem 79:9403-9413.
35. Gadgil HS, Bondarenko PV, Pipes G, Rehder D, McAuley A, Perico N, Dillon T, Ricci M, Treuheit M. 2007. The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci 96:2607-2621.
36. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC. 2005. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16:1282-1290.
37. Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, et al. 2013. Apotent anti-CD70 antibody-drug conjugate combiningadimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 24:1256-1263.
38. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, et al. 2003. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465.
39. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, et al. 2013. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122:1455-1463.
40. Costantino HR, Schwendeman SP, Langer R, Klibanov AM. 1998. Deterioration of lyophilized pharmaceutical proteins. Biochemistry (Mosc) 63:357-363.
41. Lai MC, Topp EM. 1999. Solid-state chemical stability of proteins and peptides. J Pharm Sci 88:489-500.
42. Rathore N, Rajan RS. 2008. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24:504-514.
43. Remmele RL, Krishnan S, Callahan WJ. 2012. Development of stable lyophilized protein drug products. Curr Pharm Biotechnol 13:471-496.
44. Tyler-Cross R, Schirch V. 1991. Effects of amino acid sequence, buffers, and ionic strengthonthe rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem 266:22549-22556.
45. Zhang B, Yang Y, Yuk I, Pai R, McKay P, Eigenbrot C, Dennis M, Katta V, Francissen KC. 2008. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal Chem 80:2379-2390.
46. Kaschak T, Boyd D, Yan B. 2011. Characterization of glycation in an IgG1 by capillary electrophoresis sodium dodecyl sulfate and mass spectrometry. Anal Biochem 417:256-263.
47. Miller AK, Hambly DM, Kerwin BA, Treuheit MJ, Gadgil HS. 2011. Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody. J Pharm Sci 100:2543-2550.
48. Vakos HT, Black B, Dawson B, Hefford MA, Kaplan H. 2001. In vacuo esterification of carboxyl groups in lyophilized proteins. J Protein Chem 20:521-531.
49. Richter SN, Fabris D, Moro S, Palumbo M. 2005. Dissecting reactivity of clerocidin toward common buffer systems by means of selected drug analogues. Chem Res Toxicol 18:35-40.
50. Richter SN, Leo E, Giaretta G, Gatto B, Fisher LM, Palumbo M. 2006. Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage. Nucleic Acids Res 34:1982-1991.
51. Akagawa M, Sasaki D, Kurota Y, Suyama K. 2005. Formation of alpha-aminoadipic and gamma-glutamic semialdehydes in proteins by the maillard reaction. Ann NY Acad Sci 1043:129-134.
52. Valliere-Douglass JF, Connell-Crowley L, Jensen R, Schnier PD, Trilisky E, Leith M, Follstad BD, Kerr J, Lewis N, Vunnum S, et al. 2010. Photochemical degradation of citrate buffers leads to covalent acetonation of recombinant protein therapeutics. Protein Sci 19:2152-2163.
53. Chumsae C, Gifford K, Lian W, Liu H, Radziejewski CH, Zhou ZS. 2013. Arginine modifications by methylglyoxal: Discovery in a recombinant monoclonal antibody and contribution to acidic species. Anal Chem 85:11401-11409.
54. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, et al. 2006. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124.
55. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, et al. 2008. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290.
56. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, Senter PD. 2008. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19:759-765.
57. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, et al. 2012. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189.
58. Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, Ma S. 2008. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: Where it is, how it got there, and how it affects charge-based behavior. Anal Biochem 373:179-191.
59. Zhang L, Lilyestrom W, Li C, Scherer T, van Reis R, Zhang B. 2011. Revealing a positive charge patch on a recombinant monoclonal antibody by chemical labeling and mass spectrometry. Anal Chem 83:8501-8508.